COVID-19

Samples and controls for COVID-19 research

For the research of COVID-19 and its pathogen SARS-CoV-2, we offer various samples, including single donations (panels and bulks) for the validation of test systems. Furthermore, we produce pools and controls. These are mainly used for external and internal quality control (e.g. proficiency testing). For this purpose, a selection of standard products is available with SARS-CoV-2 positive and negative samples as well as with other coronaviruses.

The in.vent products are for research or manufacturing purposes only and are therefore not intended for direct therapeutic or diagnostic use in humans or animals. Furthermore, we follow the highest ethical standards in the procurement of samples. If you have any questions in this regard, please do not hesitate to contact us!

Why is research into COVID-19 important?

COVID-19 (coronavirus disease 2019) is a viral disease caused by the SARS-CoV-2 coronavirus. It was first discovered in Wuhan in 2019 and has spread worldwide. It is mainly caused by droplet infection, but also by smear infection or infection through the conjunctiva of the eyes.

Our portfolio includes the following Biomarkers:

Viral Infectious Diseases

  • CMV
  • EBV
  • Measles
  • Mumps
  • diagnosed Influenza

Non-SARS Corona Viruses

  • HKU1
  • NL63
  • OC43
  • 229E

SARS-CoV-2

Composition and documentation of COVID-19 and SARS-CoV-2 samples

Our samples consist of native human bio-material without additives. All titres are based on current availability. In addition, we provide detailed information for each product, including: Titer, Volume, Matrix, Shelf Life, Test Kit and Test Manufacturer. For single donors, we also add information such as age, gender of the donor and the measured laboratory result.

Furthermore, you have the possibility to send us individual enquiries regarding matrix, volume and biomarker. Our Inquiry Form is available for this purpose.

Es sind zwei Innovationsassistentinnen über den europäischen Sozialfond für den Aufbau folgender Innovationen:

  • Die geplante betriebliche Innovation soll zum Aufbau des Teilbereichs in.vent Clinical Services (ICS) beitragen, um die Dienstleistung des Planens, Durchführens und Dokumentierens von diagnostischen Studien für die diagnostische Industrie, entsprechend der neuesten gesetzlichen Vorgaben anbieten und durchführen zu können.
  • Entwicklung und Implementierung von plattformunabhängigen Testsystemen, und Rohstoffen, spezifischer humaner Biomaterialien sowie Kontrollproben zur Verbesserung der Schilddrüsen-Diagnostik als IVD-Produktpalette.
Qualification measures:

Growing Organisation; Adaption of Qualification to new market demands, project areas and fields of production

To achieve the goal, that invent persist at the international market, qualification for current and new employees were conducted as follows:

  • training in online-marketing,
  • in contract law and
  • in business basics for executive leadership with scientific background.

New employees acquired competences in the fields of:

  • data protection,
  • medical devices advice,
  • internal auditing,
  • performance assessment of in-vitro diagnostics as well as
  • project management

In the field of production, knowledge of macro programming was gained for digitization.

The measures were funded through the European Social Fund and the state of Brandenburg for the period 2019 – 2021.